Considerations in assessing the immunotoxic potential of investigational drugs

被引:0
|
作者
Hastings K.L. [1 ]
Ahn C.-H. [1 ]
Alam S.N. [1 ]
Aszalos A. [1 ]
Choi Y.S. [1 ]
Jessop J.J. [1 ]
Weaver J.L. [1 ]
机构
[1] Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland
来源
Drug information journal : DIJ / Drug Information Association | 1997年 / 31卷 / 4期
关键词
Allergenicity; Immunotoxicity; Pharmaceuticals;
D O I
10.1177/009286159703100438
中图分类号
学科分类号
摘要
Determination of the potential for an investigational drug to adversely affect the immune system is a standard component of nonclinical toxicology studies. Potential adverse immune effects include drug-induced hypersensitivity, immunosuppression, autoimmunity, immunostimulation, and drug antigenicity. Although immunotoxicology studies are rarely incorporated under a single heading in submissions, sponsors frequently conduct specialized assays to determine immunotoxic effects. Skin and respiratory sensitization studies are usually conducted if a drug is to be administered topically or by the inhalation route, respectively. These studies are designed to model clinical effects rather than to determine sensitization potential based on underlying immune mechanisms. Passive and active anaphylaxis assays are used to demonstrate biological effects indicative of drug antigenicity. Studies designed to determine immunosuppressive or immunostimulatory potential are often conducted when these effects are related to pharmacodynamic properties of the drug. Nonclinical studies designed to detect potential to induce autoimmune reactions are rarely conducted, primarily due to a lack of adequately characterized assays. In addition, newer assays designed to determine sensitization and autoimmunity-inducing potential are being evaluated. © 1997, Drug Information Association. All rights reserved.
引用
收藏
页码:1357 / 1361
页数:4
相关论文
共 50 条
  • [21] In vitro identification of the possible immunotoxic potential of RNA drugs focusing on four specific stress pathways
    Bettinsoli, V.
    Melzi, G.
    Pantaleoni, S.
    Marchese, I.
    Marinovich, M.
    Corsini, E.
    TOXICOLOGY LETTERS, 2024, 399 : S72 - S73
  • [22] Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus
    Adetomiwa A. Adeniji
    Kirsten E. Knoll
    Du Toit Loots
    Applied Microbiology and Biotechnology, 2020, 104 : 5633 - 5662
  • [23] Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus
    Adeniji, Adetomiwa A.
    Knoll, Kirsten E.
    Loots, Du Toit
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2020, 104 (13) : 5633 - 5662
  • [24] BLOOD PRESSURE ABNORMALITIES IN SCHIZOPHRENIC PATIENTS - SOME CONSIDERATIONS RELEVANT TO CLINICAL TESTING OF INVESTIGATIONAL DRUGS
    BISHOP, MP
    MASON, LB
    GALLANT, DM
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1968, 10 (07): : 315 - &
  • [25] Considerations in estimating social and economic impacts of immunotoxic agents
    Blanciforti, Laura A.
    Luster, Michael I.
    HUMAN AND ECOLOGICAL RISK ASSESSMENT, 2006, 12 (05): : 888 - 903
  • [26] Investigational drugs for the treatment of dysmenorrhea
    Mardon, Amelia K.
    Whitaker, Lucy
    Farooqi, Toobah
    Girling, Jane
    Henry, Claire
    Ee, Carolyn
    Tewhaiti-Smith, Jordan
    Armour, Mike
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (04) : 347 - 357
  • [27] Investigational drugs for diabetic nephropathy
    Cortinovis, Monica
    Cattaneo, Dario
    Perico, Norberto
    Remuzzi, Giuseppe
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (10) : 1487 - 1500
  • [28] New and investigational antiepileptic drugs
    Striano, Pasquale
    Striano, Salvatore
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (12) : 1875 - 1884
  • [29] Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits
    Fountzilas, Elena
    Said, Rabih
    Tsimberidou, Apostolia M.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (02) : 155 - 162
  • [30] Investigational drugs to treat hemophilia
    Franchini, Massimo
    Marano, Giuseppe
    Pati, Ilaria
    Veropalumbo, Eva
    Vaglio, Stefania
    Pupella, Simonetta
    Masiello, Francesca
    Cruciani, Mario
    Mengoli, Carlo
    Liumbruno, Giancarlo Maria
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (03) : 295 - 301